Avalon Pharma, one of the fastest-growing pharmaceutical companies in the Kingdom of Saudi Arabia, has signed a strategic manufacturing agreement with Al-Dawaa Medical Services Company (DMSCO).
Under the agreement, the two companies will collaborate to manufacture a range of essential medications required by the local Saudi market, ensuring their sustainable availability while also preventing shortages, thereby ensuring the security of local pharmaceutical supply.
The companies have pledged to work together to provide high-quality medications at competitive prices, helping to alleviate the financial burden on citizens and making medications more accessible.
Both companies will strive to improve customer services in terms of distribution, delivery, and providing necessary information about the medications, which will positively impact both customers and suppliers.
This collaboration reaffirms the ongoing support of both companies for the significant and rapid advancement of the healthcare sector in the Kingdom of Saudi Arabia, which is expected to enhance efficiency and quality, marking a significant step towards a bright future.
Mohamed Maher Alghannam MD & CEO Avalon Pharma
“This strategic partnership with DMSCO marks a pivotal moment in our journey to support the Kingdom’s healthcare objectives. By localizing the production of essential medications, we are not only ensuring a sustainable supply but also contributing to the overall economic and social well-being of our nation. We are excited about the positive impact it will have on the healthcare sector in Saudi Arabia.”
The agreement reflects Avalon Pharma’s continued commitment to investing in growth and contributing to enhancing national drug and health security, in line with Saudi Vision 2030 and the National Transformation Program.
The collaboration between Avalon Pharma and DMSCO supports the Kingdom of Saudi Arabia’s ambitious initiatives geared towards localizing the manufacturing of vital medications, thereby boosting the Kingdom of Saudi Arabia’s ability to achieve national drug and health security.
Avalon Pharma aims to enhance its growth through innovative marketing strategies, achieving continued milestones such as registering new production lines in its factory, achieving profitability, and launching Avalon Pharma’s fourth manufacturing facility in the Kingdom.
Both companies expressed their optimism about the fruitful collaboration, emphasizing the importance of this step in supporting the healthcare sector in the Kingdom of Saudi Arabia and achieving positive changes that enhance efficiency and quality in the healthcare system, in line with the ongoing health transformation taking place both locally and internationally.
